Adv Search
 
  Office
  About
  Links
PUBMed
www.dxy.cn
More>>  
 
  Visited
    Current Issue
2016 Vol. 3, No. 4
Published: 2016-12-09
 
234 JC724 extraction and its effect on colorectal cancer
1DENG Li, 2DING Yan, 1, 3RAO Ben-qiang, 1YANG Jun
 Objective To standardize the extraction condition of JC724 from natural plants, and to test the effect of JC724 on
colorectal cancer. Methods Standard operating procedure (SOP) was adopted to extract JC724 from preset medicine homologous
food and traditional anti-tumor Chinese medicine. Phytomics QC system was used to test stability of the extraction methods and to
examine the biological effect of JC724. By standardization of the extraction conditions and methods of JC724, the effect of inhibition
on colorectal cancer in vivo and in vitro was studied and compared with 5-Fu. Results 30 batches of JC724 were acquired using SOP
through ten different extraction conditions and methods (3 batches per set). Phytomics QC system was used to test for JC724. The
condition and method for the sample set which had the most stable biological activities was confirmed as standard extraction method.
During 96-hour, the highest inhibition rate on 293 cell line among JC724(20mg/ml), 5-Fu (5mg/ml), 5-Fu combined with JC724 (5-Fu:
2.5mg/ml, JC724: 10mg/ml) were 93.2%、82.1%、3.9% respectively, no effects was found in JC724 to 293 cell (P>0.05). The 96-
hour highest inhibition rate on HCT-116 among JC724, 5-Fu and 5-Fu+JC724 were 92.5%, 97.0% and 100% respectively (P>0.05).
However, the 96-hour inhibition rate on HT-29 among JC724, 5-Fu and 5-Fu+JC724 were 84.2%, 91.7% and 98.5% respectively
(P<0.05), and similar results were found in SW-480 cell line, the 96-hour inhibition rate on HT-29 among JC724, 5-Fu and 5-Fu+JC724
were 84.3%, 98.6% and 100% respectively (P<0.05). In colorectal tumor bearing mice model, the tumor inhibition rate of JC724, 5-Fu
and JC724+5-Fu were 83.95%, 85.60%and 92.07% respectively. After 9 days treatment, the weight of the control, JC724, 5-Fu and
JC724+5-Fu treated mice group were 106%, 104%, 73% and 86% of its primary weight respectively (P<0.01 among JC724, 5-Fu and
JC724+5-Fu group). Conclusions Phytomics QC system was a feasible evaluation tool for standardization of JC724, served as an
inhibitor on colorectal cancer in vivo and in vitro, which had synergistic effect with 5-Fu and might reduce the toxicity of 5-Fu.
2016 Vol. 3 (4): 234- [Abstract] ( 232 ) HTML PDF (1598 KB)  ( 140 )
239 Enteral nutrition for esophageal cancer patients with concurrent chemoradiotherapy#br#
1LV Jia-hua, 1LI Tao, 2ZHU Guang-ying, 3LI Jie, 4ZHU Shu-chai, 5WANG Jian-hua, 6XING Li-gang, 7YANG Dao-ke, 8XIE Cong-hua, 9SHENLiangfang,1LANGJinyi,10SHIHan-ping
Objective To evaluate the change of body weight, nutritional status, efficacy and safety of concurrent
chemoradiotherapy combined with or without enteral nutrition for esophageal carcinoma. Methods Patients with esophageal
carcinoma in accordance with inclusion criteria were randomly assigned to experimental group and the control group. Both groups of
patients received at least 2 cycles of chemotherapy with cisplatin and docetaxel every 3 weeks concurrent with radiotherapy. Patients
in concurrent chemoradiotherapy experimental group received enteral nutrition containing 10~25kcal/(kg·d) according to swallowing
obstruction, dietary structure, amount of food intake, in addition to regular diets. The primary end point was weight loss and the
secondary end points were nutrition related index, toxicity and clinical effect. Results Between Sep. 2014 and Feb. 2016, 88 patients
were enrolled and divided into the experimental group (n=58) and the control group (n=30). The baseline clinical characteristics of
the 2 groups were similar. The average loss of body weight of experimental group was lower than the control group [(2.26±0.64)kg
vs. (5.45±2.94)kg, P>0.05]. The average loss of body mass index in experimental group was lower than the control group (0.88±0.25
vs. 2.08±1.12, P>0.05). The nutrition related indicators such as hemoglobin, serum albumin, total lymphocyte count of experimental
group were better than the control group, there were no statistical differences except for serum albumin (P>0.05). The objective
remission rate of the experimental group was 90.4%, while the control group was 86.7% (P>0.05). In adverse reactions, experimental
group with equal or greater than grade 3 hematologic adverse reactions were significantly lower than the control group (31.1% vs. 
45.7%, P<0.05). The acute radiation esophagitis and acute radiation pneumonia were no statistical differences (P>0.05). Conclusions
Enteral nutrition can reduce the weight loss of esophageal cancer patients during chemoradiotherapy, improve nutritional status and
treatment tolerance, reduce toxicity, but we need to enroll more patients to confirm these results.
2016 Vol. 3 (4): 239- [Abstract] ( 336 ) HTML PDF (921 KB)  ( 131 )
243 Relationship between vitamin D and cancer risk and prognosis
HUANG Jing, ZHANG Cai-xia
 Objective The occurrence of cancer is increasing worldwide. It is known that diet and life style play important roles
in the incidence and progression of cancer. This review provided an overview of the association between vitamin D and cancer risk
and prognosis. Methods The published literatures about vitamin D and cancer risk and prognosis, especially Meta analysis, were
recruited for further comprehensive summary. Results Vitamin D status was inversely associated with colorectal cancer, breast
cancer, lung cancer and bladder cancer risk, and could improve the prognosis of hematological malignancies patients, however, the
association between vitamin D and risk of other cancers is still inconclusive. Conclusions Adequate vitamin D status is associated
with a lower risk of cancer, and can improve prognostic outcomes of cancer patients. More well-designed epidemiological studies are
needed for further investigation of the relationship between vitamin D and risk and prognosis of cancer.
2016 Vol. 3 (4): 243- [Abstract] ( 275 ) HTML PDF (1002 KB)  ( 197 )
250 Maintainace and regulation of lean body mass
1TANG Xi-lan, 2SHI Han-ping
 Lean body mass, which accounts for nearly half of the mass of the human body, participates in all human activities
and is closely relates to human health, living ability and quality. The quality of lean body tissue is closely related to the synthesis,
decomposition and metabolism of protein, and the quality of lean body tissue is regulated by many signal pathways in modern
medical research. Regulating signaling pathways of lean body mass includes positive and negative regulation, of which the former
one mainly involves in mammalian target of rapamycin pathway, transforming growth factor beta pathway, peroxisome proliferating
activated receptor co-activator pathway and G protein pathway and the latter one mainly involves in growth arrest and DNA damageinducible 45 pathway, nuclear factor kappa B pathway and myostatin pathway. In a conclusion, it will provide a guidance for the
clinical research and treatment of the skeletal muscle related disease by research on the regulating signaling pathways of lean body
mass.
2016 Vol. 3 (4): 250- [Abstract] ( 328 ) HTML PDF (1140 KB)  ( 166 )
261 Glyoxalase I in tumor development and progression
XU Ning-jing, MIAO Ming-yong
 Tumor metabolic changes is closely related to the occurrence and progression of human malignancies. Meanwhile
abnormal metabolism of tumor lead to the accumulation of cytotoxic metabolites such as methylglyoxal(intermediate products of
glycolysis), which are bad for cell survival. The research of recent years find that GLO I may inhibit the apoptosis of cancer cell
through the degradation of the toxic metabolite methylglyoxal which is produced in the process of carbohydrate metabolism. In
reverse, the inhibition of the expression of GLO I will accumulate methylglyoxal in cell which leads to the apoptosis of cancer cell,
thus achieve anticancer effect. This article makes some preliminary discussion on the structure and function of GLO I, its role in the
occurrence and development of tumor and relevant clinical appliance.
 
2016 Vol. 3 (4): 261- [Abstract] ( 302 ) HTML PDF (1207 KB)  ( 145 )
265 Environmental factors on targeted cancer therapy
1NIE Zhi-hua, 1LONG Meng-juan, 2FU Zhen-ming
Through slow and long-term gene-environment interactions, environmental factors (such as nutritional factors,
physical and chemical factors, patterns of life, etc.) might cause genetic mutation and affected drug-sensitivity, thus might affect
the choice or the treatment efficacy of tumor-targeted therapy. Nutritional status before cancer treatment had been considered as an
important prognostic factor in cancer chemotherapy and radiotherapy. However, in the era of cancer molecular-targeted therapy, its
prognostic values have often been ignored. As far as we known, there was no study specifically address the roles of environmental
factors including nutritional factors on tumor-targeted therapy. To throw some light on this emerging research area and provid more
basis for molecular-targeted therapy of clinical oncology, we made an review about the research progress in the effects of nutritional
factors on tumor-targeted therapy.
2016 Vol. 3 (4): 265- [Abstract] ( 296 ) HTML PDF (1408 KB)  ( 105 )
Copyright © Editorial Board of Electron J Metab Nutr Cancer
Supported by:Beijing Magtech